Featured Research

from universities, journals, and other organizations

'High-risk' organs from deceased donors safe when screened with current methods

Date:
October 25, 2013
Source:
American Society of Nephrology (ASN)
Summary:
A study has shown that after a median of 2.4 years of follow up, 86.5% of transplants of donor kidneys considered “high-risk” for infection and disease were functioning with no evidence of infections. Such “high-risk” organs are relatively safe when screened with current methods.

Approximately 10% of deceased donor kidneys are considered "high-risk" for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention. But new research suggests that many of these organs are safe and therefore should not be labeled as high-risk. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.

Researchers led by Moya Gallagher, RN (New York-Presbyterian Hospital/Columbia University Medical Center) found that since 2004, a total of 170 patients received kidneys that met CDC's high-risk criteria at Columbia University Medical Center. In addition to standard pre-transplant blood screening for HIV, HCV, and HBV, these patients were also screened by antibody and DNA testing at 6, 12, and 24 weeks post transplant. All patients received standard immunosuppressive therapy.

Among the donors, 57.1% had a history IV drug use, 25.9% had high-risk sexual behavior, 11.8% were incarcerated, 7.1% were men who had sex with men, and 4.7% had received multiple blood transfusions. The majority (77.8%) were imported from other centers, suggesting that other centers declined to use these organs. After a median of 2.4 years of follow up, 86.5% of transplants were functioning, and there was no transmission of the viral diseases in question.

The findings demonstrate the relative safety of so-called high-risk deceased donor organs when screened by current methods. These organs should probably be labeled as "identified risk" rather than "high-risk," according to the investigators.

"Utilization of these organs represents an opportunity for shortening wait time for patients while providing good outcomes and an extremely low level of risk for transmission of infections," said Gallagher. "For most deceased organ donors, the medical/social history is obtained second or third hand, and it is erroneous to assume that some of these patients do not fall into the groups that constitute the 'high-risk' classification. Therefore, we believe that the current dichotomized classification is misleading and does a disservice to those patients on the waiting list," she added.


Story Source:

The above story is based on materials provided by American Society of Nephrology (ASN). Note: Materials may be edited for content and length.


Cite This Page:

American Society of Nephrology (ASN). "'High-risk' organs from deceased donors safe when screened with current methods." ScienceDaily. ScienceDaily, 25 October 2013. <www.sciencedaily.com/releases/2013/10/131025091439.htm>.
American Society of Nephrology (ASN). (2013, October 25). 'High-risk' organs from deceased donors safe when screened with current methods. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/10/131025091439.htm
American Society of Nephrology (ASN). "'High-risk' organs from deceased donors safe when screened with current methods." ScienceDaily. www.sciencedaily.com/releases/2013/10/131025091439.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins